Now, in a new study published in the journal Cell, scientists at the Salk Institute for
Biological Studies have discovered that a synthetic form
of vitamin D, calcipotriol (a drug already approved by the FDA for the
treatment of psoriasis), deactivates the switch governing the fibrotic response in mouse liver cells, suggesting a potential new therapy for fibrotic diseases in humans.